| Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs DA Volpe, GAMM Tobin, RD Mellon, AG Katki, RJ Parker, T Colatsky, ... Regulatory Toxicology and Pharmacology 59 (3), 385-390, 2011 | 411 | 2011 |
| Variability in Caco‐2 and MDCK cell‐based intestinal permeability assays DA Volpe Journal of pharmaceutical sciences 97 (2), 712-725, 2008 | 308 | 2008 |
| Effect of sunscreen application under maximal use conditions on plasma concentration of sunscreen active ingredients: a randomized clinical trial MK Matta, R Zusterzeel, NR Pilli, V Patel, DA Volpe, J Florian, L Oh, ... JAMA, 2019 | 296 | 2019 |
| Drug-permeability and transporter assays in Caco-2 and MDCK cell lines DA Volpe Future medicinal chemistry 3 (16), 2063-2077, 2011 | 231 | 2011 |
| Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial Matta MK, Florian J, Zusterzeel R, Pilli NR, Patel V, Volpe DA, Yang Y, Oh L JAMA 323 (3), 256-267, 2020 | 218 | 2020 |
| Application of method suitability for drug permeability classification DA Volpe The AAPS journal 12 (4), 670-678, 2010 | 148 | 2010 |
| Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs J Li, DA Volpe, Y Wang, W Zhang, C Bode, A Owen, IJ Hidalgo Drug Metabolism and Disposition 39 (7), 1196-1202, 2011 | 120 | 2011 |
| Biopharmaceutics classification of selected β-blockers: solubility and permeability class membership Y Yang, PJ Faustino, DA Volpe, CD Ellison, RC Lyon, LX Yu Molecular pharmaceutics 4 (4), 608-614, 2007 | 106 | 2007 |
| Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests RE Parchment, M Gordon, CK Grieshaber, C Sessa, D Volpe, M Ghielmini Annals of Oncology 9 (4), 357-364, 1998 | 89 | 1998 |
| Classification of drug permeability with a Caco-2 cell monolayer assay DA Volpe, PJ Faustino, AB Ciavarella, EB Asafu-Adjaye, CD Ellison, ... Clinical Research and Regulatory Affairs 24 (1), 39-47, 2007 | 84 | 2007 |
| Validation and application of a stability-indicating HPLC method for the in vitro determination of gastric and intestinal stability of venlafaxine EB Asafu-Adjaye, PJ Faustino, MA Tawakkul, LW Anderson, XY Lawrence, ... Journal of pharmaceutical and biomedical analysis 43 (5), 1854-1859, 2007 | 80 | 2007 |
| Permeability classification of representative fluoroquinolones by a cell culture method DA Volpe AAPS PharmSci 6 (2), 1-6, 2004 | 78 | 2004 |
| Use of Different Parameters and Equations for Calculation of IC50 Values in Efflux Assays: Potential Sources of Variability in IC50 Determination DA Volpe, SS Hamed, LK Zhang The AAPS journal 16 (1), 172-180, 2014 | 71 | 2014 |
| Evaluation of transporters in drug development: current status and contemporary issues SC Lee, V Arya, X Yang, DA Volpe, L Zhang Advanced drug delivery reviews 116, 100-118, 2017 | 65 | 2017 |
| In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine [NSC-366140, PD115934] to myeloid and erythroid hematopoietic progenitors from human, murine, and … RE Parchment, DA Volpe, PM LoRusso, CL Erickson-Miller, MJ Murphy Jr, ... JNCI: Journal of the National Cancer Institute 86 (4), 273-280, 1994 | 64 | 1994 |
| Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells DA Volpe, JE Tomaszewski, RE Parchment, A Garg, KP Flora, MJ Murphy, ... Cancer chemotherapy and pharmacology 39 (1-2), 143-149, 1996 | 59 | 1996 |
| Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review DA Volpe, Y Xu, CG Sahajwalla, IR Younis, V Patel Journal of pharmaceutical sciences 107 (12), 2983-2991, 2018 | 56 | 2018 |
| Transporter assays as useful in vitro tools in drug discovery and development DA Volpe Expert opinion on drug discovery 11 (1), 91-103, 2016 | 50 | 2016 |
| Effect of uremic serum and uremic toxins on drug metabolism in human microsomes DA Volpe, GA Tobin, F Tavakkoli, TC Dowling, PD Light, RJ Parker Regulatory Toxicology and Pharmacology 68 (2), 297-303, 2014 | 45 | 2014 |
| Impact of the US FDA “biopharmaceutics classification system”(BCS) guidance on global drug development MU Mehta, RS Uppoor, DP Conner, P Seo, J Vaidyanathan, DA Volpe, ... Molecular pharmaceutics 14 (12), 4334-4338, 2017 | 41 | 2017 |
